Pharmacokinetic evaluation of marbofloxacin after intravenous administration at different ages in llama crias, and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation

被引:5
|
作者
Rubio-Langre, Sonia [1 ]
Aguilar-Sola, Soledad [2 ]
Matias Lorenzutti, Augusto [2 ]
San Andres, Manuel I. [1 ]
De Lucas, Jose J. [1 ]
Litterio, Nicolas J. [2 ]
机构
[1] Univ Complutense Madrid, Fac Vet, Dept Toxicol & Farmacol, Madrid, Spain
[2] Univ Catolica Cordoba, Fac Ciencias Agr, IRNASUS CONICET, Av Armada Argentina 3555 X5016DHK, Cordoba, Argentina
关键词
Llamas; Marbofloxacin; Monte Carlo simulation; pharmacodynamics; pharmacokinetics; PRUDENT USE; RESISTANCE; BACTERIA; DOSAGE; SUSCEPTIBILITY; ENROFLOXACIN; DISPOSITION; EMERGENCE;
D O I
10.1111/jvp.12698
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In llama crias (tekes), Escherichia coli and Staphylococcus aureus are major pathogens, and marbofloxacin could be a suitable choice. The objectives of this study were (a) to evaluate the serum pharmacokinetics of marbofloxacin (5 mg/kg) after intravenous administration in tekes and simulate a multidose regimen; (b) to emulate pharmacokinetic profiles after single dose and steady-state conditions by Monte Carlo simulation (c) to determine the MIC of regional strains of Escherichia coli and Staphylococcus aureus; (d) to perform a PK/PD analysis by Monte Carlo simulation. Pharmacokinetics of marbofloxacin was evaluated in six animals at 3, 10, 24, 50, and 80 days after birth. Marbofloxacin were determined by HPLC. A steady-state multi-dose simulation was carried out, and concentration-time profiles were generated by Monte Carlo simulation. MIC of marbofloxacin against regional E. coli and S. aureus strains were also determined. Finally, a PK/PD analysis was conducted by Monte Carlo simulation. After pharmacokinetic analysis, clearance showed a trend to increase (0.14 and 0.18 L kg(-1) hr(-1)), and AUC (36.74 and 15.21 mu g hr(-1) ml(-1)) and Vss (3.06 and 3.37 L/kg) trended to decrease at 3 and 80 days-old, respectively, showing accumulation similar to 50% in animals with 3 days. All strains tested of E. coli (MIC90 = 0.06 mu g/ml) and S. aureus (MIC90 = 0.25 mu g/ml) were susceptible to marbofloxacin. PK/PD analysis suggests that the therapeutic regimen of marbofloxacin could be effective for infections caused by E. coli strains in animals between 3 and 80 days, with a CFR for C-max/MIC > 10 of 100% and for AUC(24)/MIC > 125 of 99.99%; and for infections produced by S. aureus in animals between 3 and 24 days old, with a CFR for C-max/MIC > 10 of 93.08% and for AUC(24)/MIC > 60 of 97.01%, but a higher dose should be used in older animals, because PK/PD endpoints were not met.
引用
收藏
页码:861 / 870
页数:10
相关论文
共 50 条
  • [21] Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole
    Sprandel, Kelly A.
    Drusano, George L.
    Hecht, David W.
    Rotschafer, John C.
    Danziger, Larry H.
    Rodvold, Keith A.
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2006, 55 (04) : 303 - 309
  • [22] Pharmacokinetic modeling and Monte Carlo simulation of ondansetron following oral administration in dogs
    Baek, I. -H.
    Lee, B. -Y.
    Kang, J.
    Kwon, K. -I.
    [J]. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2015, 38 (02) : 199 - 202
  • [23] Pharmacokinetic/Pharmacodynamic Analysis of Daptomycin Against Staphylococcus aureus and Enterococcus faecium in Pediatric Patients by Monte Carlo Simulation
    Wei, Xiao-Chen
    Zhao, Ming-Feng
    Li, Xin
    Xiao, Xia
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (06): : 768 - 774
  • [24] Rifampin breakpoint for Acinetobacter baumannii based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation
    Antonio Lepel, Jose
    Garcia-Cabrera, Emilio
    Victoria Gil-Navarro, Maria
    Aznar, Javier
    [J]. REVISTA ESPANOLA DE QUIMIOTERAPIA, 2012, 25 (02) : 134 - 138
  • [25] Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration
    Fernández-Varón, E
    Bovaira, MJ
    Espuny, A
    Escudero, E
    Vancraeynes, D
    Cárceles, CM
    [J]. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2005, 28 (04) : 343 - 348
  • [26] Pharmacokinetic-pharmacodynamic integration of orbifloxacin in rabbits after intravenous, subcutaneous and intramuscular administration
    Marin, P.
    Fernandez-Varon, E.
    Escudero, E.
    Vancraeynest, D.
    Carceles, C. M.
    [J]. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2008, 31 (01) : 77 - 82
  • [27] Pharmacokinetic-pharmacodynamic integration of danofloxacin after intravenous, intramuscular and subcutaneous administration to rabbits
    Fernandez-Varon, E.
    Marin, P.
    Escudero, E.
    Vancraeynest, D.
    Carceles, C. M.
    [J]. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2007, 30 (01) : 18 - 24
  • [28] Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats
    Woo, Sukyung
    Krzyzanski, Wojciech
    Jusko, William J.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 319 (03): : 1297 - 1306
  • [29] Evaluating posaconazole dosing regimens of the different formulations against Aspergillus spp. in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation
    Wei, Xiao-Chen
    Zhao, Ming-Feng
    Li, Xin
    Xiao, Xia
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (04)
  • [30] Evaluating amikacin dosage regimens in intensive care unit patients: A pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation
    Zazo, Hinojal
    Martin-Suarez, Ana
    Lanao, Jose M.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 (02) : 155 - 160